These are results from a market research that took place from December 2012 - August 2013. Questionnaires for both users and healthcare professionals were used. The research aimed at collecting data on how the product and its features are perceived among users and healthcare professionals.
In total 389 users and 95 healthcare professionals responded. Some users had more than 30 years of experience, while others had only just begun self-catheterization. Average age of participants was 55 years (varying from 9-89).
Countries included were Sweden, Norway, Denmark, UK, the Netherlands, France, Germany and Switzerland.
The three main reasons for catheterization were SCI (para-/tetraplegia), MS and different prostate diagnosis. 17 % of the users had slightly reduced hand function and 5 % stated that their hand function was considerably reduced. 41 % used a wheelchair and 97 % of the users catheterized themselves.
The three major advantages with LoFric Origo were:
LoFric® is the registered trademark of Wellspect HealthCare.